Abstracts tagged "adverse events and rheumatoid arthritis (RA)"

Abstract Number: 269 • ACR/ARHP Annual Meeting 2018
Adverse Event Reporting Rates and Placebo/Standard-of-Care-Arm American College of Rheumatology Responses Vary By Region in Rheumatoid Arthritis Trials
Katie Tuckwell, Edmond Teng, Jenny Chia, Daisy Lee, Joshua Galanter, Jodie Peake and Daniel Keebler, Genentech, Inc., South San Francisco, CA
Background/Purpose: Clinical trials are becoming increasingly globalized, with more representation from Asia, Latin America, and the Russian Federation and Eastern Europe (RFEE).1 Adverse event (AE)…
Abstract Number: 1541 • ACR/ARHP Annual Meeting 2018
The Safety Profile of Iguratimod in Real Clinical Practice: Analysis of 491 Patients with Rheumatoid Arthritis
Yukihiko Ikeda¹, Ryo Rokutanda¹, Sho Fukui¹, Haruki Sawada², Mitsuru Watanabe³, Ayako Koido³, Yuko Kataoka¹, Rui Kawato⁴, Haruyuki Yanaoka⁵, Masei Suda⁶, Yuri Ohara⁷, Hiromichi Tamaki¹, Hisanori Shimizu⁶, Tokutaro Tsuda¹, Ken-ichi Yamaguchi⁸, Mitsumasa Kishimoto¹ and Masato Okada¹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Immuno-rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Immune-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁴Immuno rheumatology center, St. Luke's International Hospital, Tokyo, Japan, ⁵St. Luke's International Hospital, Tokyo, Japan, ⁶Immuno-Rheumatology Center, St luke's International hospital, Tokyo, Japan, ⁷Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁸Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan
The retention rate and safty profile of iguratimod in real clinical practice: Analysis of 456 patients with Rheumatoid arthritis. Abstract Background/Purpose: Iguratimod is one of…
Abstract Number: 15 • ACR/ARHP Annual Meeting 2016
Adverse Events and Persistency of Biologics in Rheumatoid Arthritis Patients with Interstitial Lung Disease
Dam Kim¹, Soo-Kyung Cho², Soyoung Won³, Hoon-Suk Cha⁴, Chan-Bum Choi⁵, Seung-Jae Hong⁶, Jisoo Lee⁷, Dong-Hyuk Sheen⁸, Dae-Hyun Yoo⁹, Sang-Cheol Bae¹⁰ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, ³Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁵Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁶Dept. of Rheumatology, #1 Hoeg, KyungHee University Medical Center, SEOUL, South Korea, ⁷Int Medicine, Ewha Woman's Univ Schl of Med, Seoul, Korea, Republic of, ⁸Division of Rheumatology, Eulji University, Daejeon, Korea, The Republic of, ⁹Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁰Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, Korea, The Republic of
Background/Purpose: RA associated ILD (RA-ILD) is reported as 1-58% depending on the study population and the definition of ILD, and RA-ILD is known to be…
Abstract Number: 2367 • ACR/ARHP Annual Meeting 2013
Discontinuation Of Biological Therapy Due To Adverse Drug Reactions In Rheumatoid Arthritis Patients: 12 Years Follow-Up
Luis Rodriguez-Rodriguez¹, Leticia Leon², Zulema Rosales², Cristina Lajas², Lucía Arietti², Ana B. Rodríguez-Cambrón², Cristina Martínez-Prada², Jose María Leal², Pilar Macarrón², Gloria Candelas², Juan A. Jover² and Lydia Abásolo², ¹Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: To describe in a cohort of rheumatoid arthritis (RA) patients followed up to 12 years, in standard clinical practice, the rate of biological agents…
Abstract Number: 2160 • ACR/ARHP Annual Meeting 2012
Fcγ Receptor IIIb Polymorphism Is Associated with Injection Reaction to Adalimumab in Patients with Rheumatoid Arthritis
Masako Tsukamoto¹, Yosuke Hashimoto¹, Tatsuhiro Ohshige¹, Keiko Yoshimoto², Yuko Kaneko³, Hideto Kameda² and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Dept of Internal Medicine, Keio Univ School of Medicine, Shinjuku-ku, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Biological agents targeting a specific molecule provide an effective means for therapeutic management of rheumatoid arthritis (RA), but infusion/injection reaction is a major adverse…